🧾 What This Document Is

This is a Form 8-K filing, which companies use to announce major events to investors. This particular filing has three attached exhibits that together tell one complete story: the departure of Minerva's President, Geoff Race, and the hiring of his replacement. The documents include a legal settlement, a new consulting deal, and the official press announcement.

🏢 What The Company Does

👉 In simple terms, Minerva Neurosciences is a drug development company. They don't sell medicines yet; they are a "clinical-stage" biotech. Their main focus is creating new treatments for brain and nervous system disorders (CNS diseases). Their lead candidate is a drug called roluperidone, aimed at treating the "negative symptoms" of schizophrenia (like lack of emotion or motivation).

👥 The Leadership Transition

The core event is a changing of the guard.

• Geoff Race is leaving his role as President. He has been with the company since 2010 and held many top jobs, including CFO.
• Jim O'Connor is joining as the new Chief Business Officer (CBO) and General Counsel, effective April 21, 2026.
• Why it matters: This isn't a sudden firing. The language is very positive, thanking Race for his "foundational contributions." It's framed as a planned transition, with Race staying on as a consultant. The new hire, O'Connor, has a legal and business background, suggesting the company may be preparing for more complex phases like financing, partnerships, or eventual commercialization.

💰 The Financial Settlement with Geoff Race

This is detailed in the Settlement Agreement (Exhibit 10.1). It's a legal contract to prevent future lawsuits.

• Termination Date: Race's employment ends March 31, 2026.
• Lump-Sum Payment: He gets a £30,000 termination payment (tax-free up to a UK threshold).
• Payment in Lieu of Notice (PILON): He receives a large payment for his 12-month notice period, totaling about $610,048. This covers his salary, pension, insurance, and a pro-rated bonus.
• Equity (Stock Options): This is a key benefit. All his outstanding stock options are immediately vested and he has until January 1, 2030, to exercise them. This gives him a long runway to benefit from any future stock price increases.
• The Big "Waiver": In exchange for these payments and benefits, Race agrees to waive all possible legal claims against the company and its affiliates, past or future, related to his employment.

📄 The New Consultancy Agreement

To keep Race's expertise, Minerva is hiring him as a consultant (Exhibit 10.2).

• Term: Starts April 15, 2026, runs for one year until April 14, 2027.
• Role & Duties: He will advise the CEO on strategy, help with investor relations, support the commercialization plan for roluperidone, and assist with financing efforts. He must devote at least 35 hours per month.
• Pay: He will be paid £333 per hour (plus VAT), with a minimum of 35 hours per month invoiced. This could total around £139,860 over the year for the minimum hours.
• Key Point: This agreement confirms Race's departure from formal leadership but keeps him involved in a significant advisory capacity during the transition.

📦 What This Signals for Minerva

👍 Strengths: The transition is orderly and amicable. Retaining Race as a consultant provides continuity. Hiring an experienced CBO/General Counsel like O'Connor, who has a track record in financings and FDA clearances, is a strong move for a clinical-stage company approaching late-stage trials. ⚠️ Risks: Any leadership change creates some uncertainty, especially for a small biotech. The company's success is heavily tied to the upcoming Phase 3 trial for roluperidone. The effectiveness of the new leadership team in executing this trial and securing funding will be critical.

📅 What's Next

The immediate focus is the leadership handover, with Jim O'Connor starting on April 21. The company's stated strategic goal remains unchanged: successfully running the next Phase 3 trial for roluperidone for the negative symptoms of schizophrenia, aiming for potential FDA approval.

🧠 The Analogy

This filing is like a planned succession in a family business. The long-serving "family member" (Race) who helped build the house is stepping back from day-to-day management but is staying on as a trusted advisor. Meanwhile, a seasoned "outside expert" (O'Connor) is being brought in to guide the business through its next major challenge—taking its key product to market.

📇 Key Contacts & People

• Remy Luthringer: Executive Chairman & CEO, Minerva Neurosciences. (Signatory on agreements)
• Geoff Race: Departing President, now Consultant. Email: [email protected]
• Jim O'Connor: New Chief Business Officer & General Counsel.
• Frederick Ahlholm: Chief Financial Officer, Minerva Neurosciences. (Investor inquiries)
  • Email: [email protected]
• Corey Davis, Ph.D.: LifeSci Advisors, LLC. (Investor inquiries)
  • Phone: 212-915-2577
  • Email: [email protected]
• Alex Fisher: Legal Adviser to Geoff Race, Goodwin Procter (UK) LLP.

🧩 Final Takeaway

Minerva Neurosciences is executing a smooth leadership transition, thanking a long-time president while hiring experienced legal/business talent to steer the company through its crucial Phase 3 trial for its schizophrenia drug. The exit package secures a legal waiver for the company, and the new consultancy maintains access to institutional knowledge.